fluorouracil has been researched along with 3,8-dihydroxy-6h-dibenzo(b,d)pyran-6-one in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellesia, A; Espín, JC; González-Sarrías, A; Tomás-Barberán, FA; Tomé-Carneiro, J | 1 |
1 other study(ies) available for fluorouracil and 3,8-dihydroxy-6h-dibenzo(b,d)pyran-6-one
| Article | Year |
|---|---|
The ellagic acid-derived gut microbiota metabolite, urolithin A, potentiates the anticancer effects of 5-fluorouracil chemotherapy on human colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bacteria; Caco-2 Cells; Cell Cycle; Colonic Neoplasms; Coumarins; Cyclin A; Cyclin B1; Ellagic Acid; Fluorouracil; Gastrointestinal Microbiome; HT29 Cells; Humans | 2015 |